UY30745A1 - Inhibidor de factor xa - Google Patents

Inhibidor de factor xa

Info

Publication number
UY30745A1
UY30745A1 UY30745A UY30745A UY30745A1 UY 30745 A1 UY30745 A1 UY 30745A1 UY 30745 A UY30745 A UY 30745A UY 30745 A UY30745 A UY 30745A UY 30745 A1 UY30745 A1 UY 30745A1
Authority
UY
Uruguay
Prior art keywords
amide
phenyl
factor inhibitor
pyrazol
pyridin
Prior art date
Application number
UY30745A
Other languages
English (en)
Inventor
Jeremy John Edmunds
Brian Matthew Samas
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39032289&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY30745(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY30745A1 publication Critical patent/UY30745A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Composiciones farmacéuticas de 5-{[2-Fluoro-4-(2-oxo-2H-piridin-1-il)-fenil]-amida} 1-[(4-cloro-fenil)-amida] del ácido (R)-5-metil-4,5-dihidro-pirazol-1,5-dicarboxílico, procedimientos y procedimientos de uso del compuesto o de las composiciones farmacéuticas del mismo para tratar enfermedades caracterizadas por trombosis anomala en mamíferos. Forma cristalina de 5-{[2-fluoro-4-(2-oxo-2H-piridin-1-il)-fenil]-amida} 1-[(4-cloro-fenil)-amida] del ácido (R)-5- metil-4,5-dihidro-pirazol-1,5-dicarboxílico.
UY30745A 2006-11-29 2007-11-27 Inhibidor de factor xa UY30745A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86771406P 2006-11-29 2006-11-29

Publications (1)

Publication Number Publication Date
UY30745A1 true UY30745A1 (es) 2008-07-03

Family

ID=39032289

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30745A UY30745A1 (es) 2006-11-29 2007-11-27 Inhibidor de factor xa

Country Status (11)

Country Link
US (1) US20080171773A1 (es)
EP (1) EP2086962A1 (es)
JP (1) JP2010511034A (es)
AR (1) AR063977A1 (es)
CA (1) CA2670595A1 (es)
CL (1) CL2007003349A1 (es)
GT (1) GT200700105A (es)
PE (1) PE20081498A1 (es)
TW (1) TW200831090A (es)
UY (1) UY30745A1 (es)
WO (1) WO2008065503A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2138178A1 (en) * 2008-06-28 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Oxazolidninones for the treatment fo chronic obstructive pulmonary disease (COPD) and/or asthma
JP5605029B2 (ja) * 2010-07-06 2014-10-15 住友化学株式会社 化合物、樹脂及びレジスト組成物
CN104610257B (zh) * 2015-02-14 2016-06-01 佛山市赛维斯医药科技有限公司 一类含酰胺结构的FXa抑制剂、制备方法及其用途
CN104725374B (zh) * 2015-02-14 2016-08-24 佛山市赛维斯医药科技有限公司 一种含双酰胺基和腈基苯结构的FXa抑制剂及其用途
CN104860942B (zh) * 2015-02-14 2016-08-24 佛山市赛维斯医药科技有限公司 一种含双酰胺基和硝基苯基结构的FXa抑制剂及其用途
CN104610259B (zh) * 2015-02-14 2016-06-01 佛山市赛维斯医药科技有限公司 含酰胺和氮杂环结构的FXa抑制剂、制备方法及其用途
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) * 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) * 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) * 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) * 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
DE4326465A1 (de) * 1993-01-20 1995-02-09 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade

Also Published As

Publication number Publication date
EP2086962A1 (en) 2009-08-12
JP2010511034A (ja) 2010-04-08
AR063977A1 (es) 2009-03-04
PE20081498A1 (es) 2008-11-08
TW200831090A (en) 2008-08-01
CL2007003349A1 (es) 2008-06-06
GT200700105A (es) 2008-11-04
CA2670595A1 (en) 2008-06-05
US20080171773A1 (en) 2008-07-17
WO2008065503A1 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
UY30745A1 (es) Inhibidor de factor xa
NO20084923L (no) N-(2-thiazolyl)-amid derivater som GSK-3 inhibitorer
LTC2091918I2 (lt) Junginiai ir kompozicijos, kaip proteinkinazės inhibitoriai
MX2010012298A (es) Activadores de glucocinasa.
MY150542A (en) Cmet inhibitors
JO2985B1 (ar) مثبطات كينازmapk/erk
AR078766A1 (es) Formas solidas de n-(4-(7-azabiciclo(2.2.1) heptan-7-il)-2-( trifluorometil) fenil)-4-oxo-5-(trifluorometil)-1,4- dihidroquinolina-3-carboxamida
WO2007143434A3 (en) Indazole and isoindole derivatives as glucokinase activating agents
EA201200653A1 (ru) Гетариламинохинолины
NO20084850L (no) MGLUR5 modulatorer I
WO2010111626A3 (en) Poly (adp-ribose) polymerase (parp) inhibitors
TN2010000131A1 (en) Polo-like kinase inhibitors
WO2008103277A3 (en) Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
ATE510827T1 (de) Inhibitoren von proteinkinasen
SV2009002865A (es) Uso de oxazolidinonas para el tratamiento y profilaxis de microangiopatias
EA200801716A1 (ru) Тиазольные соединения и их применение
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
NO20084418L (no) Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
GB0625648D0 (en) Compounds
BRPI0815715A2 (pt) compostos 5-(-4-(haloalcóxi)fenil)pirimidina-2-amina e composições como inibidores de quinases.
NO20084458L (no) IL-8-reseptorantagonister
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
ATE486601T1 (de) Verwendung von 3- (4-amino-1-oxo-1,3-dihydro- isoindol-2-yl)-piperidin--2,6-dion zur behandlung von mantelzelllymphomen
MX2010008583A (es) Novedosos formas cristalinas de acido 4-[4-(2-adamantilcarbamoil)- 5-ter-butil-pirazol-1-il]benzoico.
MA32727B1 (fr) Pyrazolylaminopyridines au titre d'inhibiteurs de fak

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170802